Fayez Sarofim & Co
MRNA icon

Fayez Sarofim & Co’s Moderna MRNA Stock Holding History

Fayez Sarofim & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,050
Closed -$267K – 333
2021
Q4 		$267K Sell
1,050
-750
-42% -$219K ﹤0.01% 311
2021
Q3 		$693K Hold
1,800
– – ﹤0.01% 221
2021
Q2 		$423K Hold
1,800
– – ﹤0.01% 257
2021
Q1 		$236K Buy
+1,800
New +$261K ﹤0.01% 276

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fayez Sarofim & Co's MRNA Position: Q1 2022 in Review

Fayez Sarofim & Co sold out of Moderna (MRNA) in Q1 2022, closing a stake of 1,050 shares — an estimated $267K sold.

Fayez Sarofim & Co first reported a position in MRNA in Q1 2021 and held it in 4 quarters. The position peaked at $693K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Fayez Sarofim & Co reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Fayez Sarofim & Co sold 1,050 Moderna shares in Q1 2022, an estimated $267K.
  • Fayez Sarofim & Co first reported a position in Moderna in Q1 2021 and held it in 4 quarters.
  • Fayez Sarofim & Co's Moderna position peaked at $693K in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Fayez Sarofim & Co's 13F filing for Q1 2022, filed 16 May 2022.